Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Grp LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 30.00p 28.00p 32.00p - - - 163.00 16:29:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.3 -0.1 - 10.94

Salvarx Grp Share Discussion Threads

Showing 76 to 97 of 100 messages
Chat Pages: 4  3  2  1
DateSubjectAuthorDiscuss
27/3/2017
22:16
www.proactiveinvestors.co.uk/columns/northland-capital-partners-view-on-the-city/27337/northland-capital-partners-view-on-the-city-immupharma-plc-salvarx SalvaRx (LON:SALV) – BUY*: New investment Market Cap: £11m; Current Price: 29p; Target Price: 149p Investment in Rift Biotherapeutics Inc. SalvaRx announced that it has entered into an agreement to invest in Rift Biotherapeutics Inc. (Rift), a private, Delaware-domiciled biotechnology company focused on the development of antibodies for use in oncology. Under the terms of the agreement, SalvaRx will invest US$1,000,000 for an initial holding of approximately 30% (including new shares issued on the conversion of a US$90,000 convertible loan already provided to Rift) in the company. Subject to Rift achieving certain development milestones with this initial funding, SalvaRx has the option to invest up to an additional US$1,500,000 at the same valuation and to acquire all outstanding shares of Rift in exchange for new shares in SalvaRx on the same basis. The initial investment has been funded from existing cash resources. Rift, an early stage research and development company, was founded in 2015 in order to discover and develop first-in-class antibodies implicated in the inflammatory tumour and tumour infiltrating immune cells microenvironment. NORTHLAND CAPITAL PARTNERS VIEW: SalvaRx continues delivering on its expansion strategy of building a broad portfolio of immune-oncology assets. Rift represents SalvaRx’s fourth immune-oncology portfolio company. The group has discovered several candidate antibodies to novel immune check point targets. The group’s novel non T-cell based immunotherapy targets offer complementary approaches to the current standard of care in this area. The market for immuno-oncology products is forecast to expand to $80bn by 2020.
the stigologist
27/3/2017
09:27
Agreed, with the added kicker of a restricted free float - if there is reason for it to fly, it should really go for it.
spectoacc
27/3/2017
09:21
Patience is the virtue in this sort of investment. One may hit the jackpot one day. Good luck.
kingston78
27/3/2017
08:03
Thanks, seems to have caused a few buys first thing in a negative market.
spectoacc
25/3/2017
21:56
SalvaRx one of Jim Mellon's featured 'longs' at Master Investor conference this weekend.Hang in there.Fig.
fig1
14/3/2017
15:39
All gone quiet - still waiting for news on first patient dosing, and will then have to wait for news on how that's gone.
spectoacc
03/3/2017
21:35
Yes,big swings possible short term but I'm hoping for that money fountain JM speaks about.
fig1
03/3/2017
15:21
Mellon needs to start delivering here. Whineyfroth having a good laugh at all the perceived 'failures' from his 'old friend'.
the stigologist
03/3/2017
13:48
2-3 year view needed here Spector.Good luck to you.Fig.
fig1
03/3/2017
11:20
Drifting nonetheless, and probably going to drift further, but averaged a few this morning. News will come on it, just don't know when.
spectoacc
02/3/2017
07:44
and no AIM dilution
phil1969
02/3/2017
07:29
Not learned a lot from this morning's restructuring RNS - warrant conversion at 35.5p is fine, and a reminder that 2 people hold over 73% of the co. "If" they do have some success, it'll be interesting seeing people chasing the remaining 27%.
spectoacc
02/3/2017
07:24
Delayed dilution by another name is still dilution
the stigologist
28/2/2017
23:57
Whineyfroth saying placing ahoy
the stigologist
28/2/2017
10:25
Nice to see the promised diversification of interests at SalvaRx.Fig.
fig1
28/2/2017
08:42
Nice collaboration shame it hasn't created any interest today.
phil1969
06/2/2017
22:44
The price action is very positive. Some people in the know are snapping up the shares in anticipation of good news flow. The share price is likely to move up to a higher range above 40 p soon.
kingston78
03/2/2017
11:37
Profit taking is bound to happen as the anticipated news is not yet announced, but I think the price will move up again to a new height.
kingston78
03/2/2017
08:00
MMs have only marked it down a penny so it will take continuous selling to move the price downwards. I suspect the buyer is still there waiting to see if they can pick up cheap stock. If not, the buying direct from market and AT trades will continue and I suspect we can look forward to an update from the more lucrative iOX instead.
phil1969
03/2/2017
07:52
To be fair they may not have been aware of the moneyweek comment until this week i feel this may hold today, or not fall too sharply
kristini2
03/2/2017
06:58
Only taken them 7 days to release the clarification! Still - changes nothing except timescale, and may even build up a little publicity.
spectoacc
02/2/2017
16:54
02 February 2017 SalvaRx Group plc ("SalvaRx" or "the Company") Intensity Therapeutics Inc. The Company notes the recent article in MoneyWeek Magazine about SalvaRx and Intensity Therapeutics Inc., ("Intensity") in which the Company has an 8.5 per cent. interest. The article incorrectly stated that Intensity had dosed its first patient in clinical trials. Intensity expects to dose its first patient shortly at which point a further notification will be made by SalvaRx which will contain full details of the trial including the timeframe for results.
the stigologist
Chat Pages: 4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170329 17:11:41